Key Developments: Becton Dickinson and Co (BDX)
100.83USD
24 May 2013
$0.66 (+0.66%)
$100.17
$99.57
$100.85
$99.02
835,051
1,103,367
$102.72
$71.56
Latest Key Developments (Source: Significant Developments)
Becton Dickinson And Co Declares Dividend
Becton Dickinson And Co announced that it has declared a quarterly dividend of 49.5 cents per common share, payable on June 28, 2013 to holders of record on June 7, 2013. The indicated annual dividend rate is $1.98 per share. Full Article
Becton Dickinson And Co Raises FY 2013 Guidance
Becton Dickinson And Co announced that it has raised its previously communicated guidance for fiscal 2013 on revenues and earnings per share growth. On a currency-neutral basis, revenue growth is expected to be between 4.5% and 5.0%, or an increase of 50 basis points. Reported revenue growth guidance for fiscal 2013 remains consistent with the Company's previously guided range of 3.5% to 4.0%. Reported diluted earnings per share (EPS) from continuing operations are expected to be between $5.72 and $5.75, or an increase of $0.03 from the previous guidance range. On a currency-neutral basis, earnings per share are expected to increase 100 basis points to 8.5% to 9.0%. The Company reported revenues of $7.7 billion in the fiscal 2012. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenues of $7.996 billion, and EPS of $5.71 for fiscal 2013. Full Article
Becton Dickinson And Co's BD Rx Inc Announces FDA Approves Second Drug in BD Simplist Prefilled Injectable Line of Products
BD Rx Inc., a wholly-owned subsidiary of Becton Dickinson And Co announced that the U.S. Food and Drug Administration (FDA) has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables. The second BD Simplist product to launch is Metoclopramide Injection, USP, an injectable antiemetic. BD Rx launched its first drug - BD Simplist Diphenhydramine Hydrochloride Injection, USP, an injectable antihistamine - on March 27, 2013. BD Simplist prefilled injectables are designed to help improve patient care and safety by decreasing the number of steps in the traditional vial and syringe injection sequence, reducing the potential risk of medication error. The potential for medication error exists with every injection. Clinicians perform up to 20 steps in a traditional vial and syringe injection sequence. But with BD Simplist prefilled injectables, the injection sequence is reduced to approximately 12 steps, reducing the potential risk of medication error and allowing for more focus on the patient and less on injection preparation. The Company plans to launch 20 to 30 drugs in its BD Simplist line of products during the next few years and is targeting generic injectables in doses commonly relied on by clinicians in both the hospital and surgical center settings. Full Article
Becton Dickinson And Co Announces FDA 510(k) Clearance And Commercial Launch Of BD UltraSafe PLUS Passive Needle Guard
Becton Dickinson And Co announced commercial launch of a new passive needle guard technology, BD UltraSafe PLUS. The BD UltraSafe PLUS Passive Needle Guard has received 510(k) clearance as an anti-needlestick safety device. Full Article
Becton Dickinson And Co Raises Low End Of Prior FY 2013 Guidance To A Range In Line With Analysts' Estimates
Becton Dickinson And Co announced that the Company' positive first quarter results give the confidence to raise the bottom end of fiscal 2013 guidance range on revenues and earnings per share. The Company is raising the bottom end of its previously communicated revenue growth guidance for the year of 3.5% to 4.5% to 4.0% to 4.5% on a foreign currency-neutral basis. Reported revenue growth for fiscal 2013 is expected to be between 3.5% and 4.0%. Reported diluted earnings per share from continuing operations for fiscal 2013 is expected to be between $5.69 and $5.72. On a foreign currency-neutral basis, diluted earnings per share from continuing operations are expected to grow 7.5% to 8.0% over fiscal 2012 adjusted diluted earnings per share, or 10.5% to 11.0%, excluding the estimated impact of the medical device tax that went into effect last month under the U.S. healthcare reform law. The Company reported revenues of $7.7 billion in the fiscal 2012. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenues of $7.942 billion, and EPS of $5.65 for fiscal 2013. Full Article
Becton Dickinson And Co Declares Dividend
Becton Dickinson And Co announced that it has declared a quarterly dividend of 49.5 cents per common share, payable on March 29, 2013 to holders of record on March 8, 2013. Full Article
Becton Dickinson And Co's BD PhaSeal System Receives Clearance From FDA Under Newly Created ONB Product Code
BD Medical, a segment of Becton Dickinson And Co, announced that the U.S. Food and Drug Administration (FDA) has cleared the BD PhaSeal Closed System Transfer Device (CSTD) under the newly created ONB code. The FDA clearance was based on three criteria: no escape of hazardous drug or vapor concentration, no transfer of environmental contaminants, and prevention of microbial ingress. The BD PhaSeal System is the only CSTD currently available that meets all three of these standards. Full Article
Becton Dickinson And Co Completes Acquisition of Safety Syringes, Inc
Becton Dickinson And Co announced that it has completed its acquisition of Safety Syringes, Inc., a privately held California-based company that specializes in the development of anti-needlestick devices for prefilled syringes. The financial terms were not disclosed. Full Article
Becton Dickinson And Co Increases Dividend By 10 %
Becton Dickinson And Co announced that Board of Directors has declared a quarterly dividend of 49.5 cents per common share, an increase of 10 % from the previous quarter. The dividend will be payable on December 31, 2012 to holders of record on December 10, 2012. At the current rate, the annual dividend for fiscal year 2013 would be $1.98 per share. Full Article
Becton Dickinson And Co Issues FY 2013 EPS Guidance
Becton Dickinson And Co announced that for fiscal 2013, it expects reported diluted earnings per share from continuing operations to be between $5.58 and $5.64. On a foreign currency-neutral basis, expects earnings per share to grow between 7% to 8%, or 10% to 11%, after excluding the estimated impact of the medical device tax. Full Article
UPDATE 2-Becton Dickinson earnings helped by early flu season
* Adjusted operating fiscal Q1 EPS $1.53 vs Street view of $1.24
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
